Open AccessSalivary binding antibodies induced by human immunodeficiency virus type 1 recombinant gp120 vaccine. The NIAID AIDS Vaccine Evaluation Group
Author(s) -
Geoffrey J. Gorse,
E Y Yang,
Robert B. Belshe,
P W Berman
Publication year - 1996
Publication title -
clinical and diagnostic laboratory immunology
Language(s) - English
Resource type - Journals
eISSN - 1098-6588
pISSN - 1071-412X
DOI - 10.1128/cdli.3.6.769-773.1996
Subject(s) - virology , antibody , saliva , recombinant dna , human immunodeficiency virus (hiv) , immunology , medicine , hiv vaccine , glycoprotein , virus , aids vaccines , lentivirus , biology , vaccine trial , viral disease , microbiology and biotechnology , biochemistry , gene
Salivary binding antibodies induced by candidate human immunodeficiency virus type 1 (HIV-1) vaccines in healthy, HIV-1 uninfected volunteers were assessed in a clinical trial evaluating intramuscularly injected HIV-1MN recombinant gp120 (rgp120) vaccine alone or with HIV-1IIIB rgp120 vaccine. The two rgp120 vaccines induced envelope glycoprotein-specific immunoglobulin G (IgG) and IgA antibodies in whole saliva and serum.